InsiderSignal.AI

InsiderSignal.ai

TVTX - Travere Therapeutics, Inc.

Insider Sale by Cline Christopher R. (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Cline Christopher R., serving as CFO at Travere Therapeutics, Inc. (TVTX), sold 8,327 shares at $41.91 per share, for a total transaction value of $348,974.00. Following this transaction, Cline Christopher R. now holds 116,899 shares of TVTX.

This sale represents a 7.00% decrease in Cline Christopher R.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 13, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 15, 2026, 2 days after the trade was made.

Travere Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Cline Christopher R.

CFO

Christopher R. Cline is the Chief Financial Officer (CFO) of Travere Therapeutics, Inc. (TVTX), a role he assumed effective September 1, 2022.[[1]](https://fintool.com/app/research/companies/TVTX/people/christopher-cline)[[2]](https://travere.com/our-company/leadership-and-board/chris-cline-cfa/) Aged 41, he holds a Chartered Financial Analyst (CFA) charter and a finance degree from Xavier University’s Williams College of Business.[[1]](https://fintool.com/app/research/companies/TVTX/people/christopher-cline)[[2]](https://travere.com/our-company/leadership-and-board/chris-cline-cfa/) Cline joined Travere in 2014, initially leading investor relations and corporate communications as Senior Vice President, where he built the company's IR and communications infrastructure.[[1]](https://fintool.com/app/research/companies/TVTX/people/christopher-cline)[[2]](https://travere.com/our-company/leadership-and-board/chris-cline-cfa/) Prior to Travere, Cline gained experience at Elan Corporation, plc, in global investor relations, and at Phase Forward in financial planning and analysis (FP&A).[[1]](https://fintool.com/app/research/companies/TVTX/people/christopher-cline) As CFO, he oversees corporate and strategic finance, investor relations, and financial strategy, contributing to key achievements like the full FDA approval of FILSPARI® for IgAN and revenue growth from $127.5M in 2023 to $226.7M in 2024.[[1]](https://fintool.com/app/research/companies/TVTX/people/christopher-cline)[[2]](https://travere.com/our-company/leadership-and-board/chris-cline-cfa/) Recently, on February 3, 2026, Cline sold 7,242 shares of TVTX stock at $32.12 per share, reducing his holdings to approximately 112,971 shares.[[3]](https://www.gurufocus.com/insider/220893/christopher-r.-cline)[[4]](https://www.marketbeat.com/instant-alerts/insider-selling-travere-therapeutics-nasdaqtvtx-cfo-sells-7242-shares-of-stock-2026-02-03/)[[5]](https://www.secform4.com/insider-trading/1943192.htm)

View full insider profile →

Trade Price

$41.91

Quantity

8,327

Total Value

$348,974.00

Shares Owned

116,899

Trade Date

Monday, April 13, 2026

3 days ago

SEC Filing Date

Wednesday, April 15, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Travere Therapeutics, Inc.

Company Overview

No company information available
View news mentioning TVTX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5672346

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime